Philippe VILLAIN-GUILLOT

@PVG_NOSOPHARM

CEO of , a biotech company specialized in the R&D of new molecules to combat . All views on this account are my own.

Vrijeme pridruživanja: studeni 2017.

Tweetovi

Blokirali ste korisnika/cu @PVG_NOSOPHARM

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @PVG_NOSOPHARM

  1. Je participe aujourd’hui au de . Au plaisir de vous y croiser...

    Poništi
  2. 4. velj
    Poništi
  3. 29. sij

    Very good article. What CEO Ted Schroeder points out is crucial: "we run a real risk of not only companies going bankrupt but losing the antibiotic development expertise that’s resonant within those companies, because the scientists tend to move on and do other things".

    Poništi
  4. 28. sij
    Poništi
  5. 16. sij

    Great! A new 🇫🇷 biotech VC fund is born! Dear , is in your scope of investment? It is a critical unmet medical need, especially for cancer patients who are at high risk to develop opportunistic bacterial infections.

    Poništi
  6. proslijedio/la je Tweet
    8. sij

    Nosopharm wishes you a great and successful new year 2020!

    Poništi
  7. proslijedio/la je Tweet
    8. sij

    Nosopharm vous souhaite une très bonne année 2020!

    Poništi
  8. Poništi
  9. Sure, it is a tough time for innovative SMEs whereas already compromises modern medicine. But do not underestimate SMEs' capacity for resilience. The recent $m50 good news from proves that there is still hope for the field!

    Poništi
  10. Poništi
  11. Poništi
  12. Poništi
  13. Poništi
  14. Indeed, with @Inra_Intl, we disclosed in April 2018 in the discovery of the new antimicrobial ODL from the nematophile Xenorhabdus nematophila. ODL hit a specific target, and have drug-like properties. Bibliography matters... (3/3)

    Poništi
  15. "Several dozen compounds with antimicrobial properties have been isolated from nematophiles, but these do not hit specific targets and do not appear to have drug-like properties." (2/3)

    Poništi
  16. I am always pleased to see new antibiotics from and announced, especially in : However a sentence in the discussion part of the article is uncorrect... (1/3)

    Poništi
  17. Reminds me some good old PhD time... I am still convinced that RNAP is a very interesting target for antibiotic drug discovery, with so many ways to modulate it! Kudos for this review!

    Poništi
  18. Poništi
  19. proslijedio/la je Tweet
    13. stu 2019.
    Poništi
  20. I am looking forward to attend ! The title of my talk will be: ": a new class of antibiotics against Gram-negative pathogens".

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·